Form 4: Regeneron Co-Chair Exercises Options, Sells Shares

Regeneron Pharmaceuticals' Co-Chair, President & CSO George Yancopoulos exercised stock options and subsequently sold shares to cover tax obligations.

Summary

• George Yancopoulos, Co-Chair, President & CSO of Regeneron Pharmaceuticals, Inc. (REGN), reported transactions on December 9, 2025.
• Exercised non-qualified stock options to acquire 146,815 shares of common stock at an exercise price of $555.67 per share.
• Subsequently disposed of 131,874 shares of common stock at a price of $701.51 per share, likely to cover tax obligations related to the option exercise.
• Following these transactions, direct beneficial ownership stands at 310,460 shares of common stock.
• Indirect beneficial ownership includes 71,487 shares via 2024 GRAT, 200,000 shares via 2025 GRAT, 200,000 shares via 2025 GRAT II, 5,962 shares via 401(k) Plan, 180,000 shares via Trust for Children, 101,988 shares via 2024 GRAT II, and 56,048 shares via Children.

Sentiment

Score: 5

Explanation: This is a routine insider transaction involving the exercise of stock options and a subsequent sale of shares, likely for tax purposes. It does not inherently indicate a positive or negative outlook on the company's future performance.

Positives

• Exercise of 146,815 stock options indicates the executive is realizing value from previously granted equity, often seen as a positive sign of confidence in the company's long-term performance.
• The exercise price of $555.67 is significantly lower than the sale price of $701.51, indicating a substantial gain for the executive.

Negatives

• The disposition of 131,874 shares reduces the executive's direct beneficial ownership, although a significant portion is likely for tax withholding.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Minor impact, as it is a routine executive compensation event. The executive continues to hold a significant number of shares, both directly and indirectly.

Key Dates

Keywords

Regeneron Pharmaceuticals, REGN, George Yancopoulos, Insider Trading, Stock Option Exercise, Common Stock, SEC Form 4, Executive Compensation, Equity Transaction